RNA COVID 19
Showing 1 - 25 of >10,000
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study
Withdrawn
- COVID-19
- (no location specified)
Nov 1, 2022
Host Immune Response to Novel RNA COVID-19 Vaccination
Recruiting
- COVID-19 Vaccine
- Cancer
- COVID-19 Vaccine
-
San Antonio, TexasMays Cancer Center, UT Health San Antonio
Apr 22, 2022
SARS-CoV-2 Infection, COVID-19 Trial in Sumida-ku, Fukuoka (BNT162b2, Placebo)
Completed
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2
- Placebo
-
Sumida-ku, Tokyo, Japan
- +1 more
Jan 13, 2023
COVID-19, COVID-19 Vaccine Trial (RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca)
Not yet recruiting
- COVID-19
- COVID-19 Vaccine
- RNA MCTI CIMATEC HDT 5µg
- +3 more
- (no location specified)
Sep 13, 2022
COVID-19 Virus Infection, Ovarian Function Insufficiency, Fertility Disorders Trial in Istanbul (sars cov 2 biontec vaccine)
Enrolling by invitation
- COVID-19 Virus Infection
- +3 more
- sars cov 2 biontec vaccine
-
Istanbul, Gaziosmanpaşa, TurkeyGaziosmanpasa Training and Research Hospital
Aug 3, 2022
COVID-19 Trial in Watford (rapid RT-LAMP test to detect SARS-COV-2 RNA)
Completed
- COVID-19
- rapid RT-LAMP test to detect SARS-COV-2 RNA
-
Watford, Hertfordshire, United KingdomWatford General Hospital
Apr 1, 2022
COVID-19 in Baselland: Validation of Simple and Accurate Tests
Recruiting
- Coronavirus Infectious Disease 2019 (COVID-19)
- Saliva based assay: crude RNA extraction
- +3 more
-
Liestal, SwitzerlandCantonal Office of Public Health, Economics and Health Directora
Dec 9, 2022
COVID-19 Trial (Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Not yet recruiting
- COVID-19
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
- +3 more
- (no location specified)
Dec 22, 2022
Influenza, COVID-19, RSV Infection Trial (Collection of saliva, nasopharyngeal-, nasal-, and oropharyngeal swabs)
Not yet recruiting
- Influenza
- +2 more
- Collection of saliva, nasopharyngeal-, nasal-, and oropharyngeal swabs
- (no location specified)
Mar 1, 2023
Influenza-like Illness (Including COVID-19)
Suspended
- Influenza
- +7 more
- Respiratory infections
-
London, United KingdomImperial College London
Jul 27, 2022
COVID-19, Corona Virus Infection Trial in Ann Arbor (Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine)
Recruiting
- COVID-19
- Corona Virus Infection
- Pfizer-BioNTech mRNA COVID-19 vaccine
- Moderna mRNA COVID-19 vaccine
-
Ann Arbor, MichiganUniversity of Michigan
Apr 23, 2022
Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients
Not yet recruiting
- COVID-19 Pneumonia
- ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
- plasmatic SARS-CoV-2 RNA quantification
- (no location specified)
Nov 9, 2021
Healthy Adult Volunteers Trial in Taipei City (ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine)
Completed
- Healthy Adult Volunteers
- ChAdOx1-nCov-19 (Astra-Zeneca)
- SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
-
Taipei City, X, TaiwanNational Taiwan University Hospital
Oct 16, 2022
COVID-19 Vaccines Trial in Ho Chi Minh City, Ha Noi (ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine, Placebo (normal saline),
Active, not recruiting
- COVID-19 Vaccines
- ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
- +2 more
-
Ho Chi Minh City, Ho Chi Minh, Vietnam
- +2 more
Mar 14, 2022
SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1))
Recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b5 Bivalent (WT/OMI BA.2)
- BNT162b2 Bivalent (WT/OMI BA.1)
-
Anaheim, California
- +9 more
Aug 8, 2022
Covid19, SARS-CoV Infection Trial in Seattle (Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo)
Terminated
- Covid19
- SARS-CoV Infection
- Zinc Picolinate
- +3 more
-
Seattle, WashingtonSwedish Medical Center
Jul 26, 2022
Covid-19, Protection Against COVID-19 Trial in Berlin, Mannheim (BNT162b3)
Completed
- Covid-19
- Protection Against COVID-19
- BNT162b3
-
Berlin, Germany
- +1 more
Jun 24, 2022
SARS-CoV-2 Infection, COVID-19 Trial (BNT162b5 Bivalent or BNT162b2 Bivalent 30 µg, BNT162b4 5 µg, BNT162b4 10 µg)
Not yet recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b5 Bivalent or BNT162b2 Bivalent 30 µg
- +3 more
- (no location specified)
Sep 14, 2022
Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases Trial in Cayenne (Tocilizumab, Dexamethasone)
Completed
- Coronavirus Infection
- +7 more
-
Cayenne, French GuianaCH Andrée Rosemon
Jun 7, 2022
SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2 (Omi XBB.1.5))
Not yet recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2 (Omi XBB.1.5)
-
Dublin, California
- +14 more
Aug 10, 2023
Kidney Transplant Recipients, Liver Transplant Recipients Trial in United States (Pfizer-BioNTech COVID-19 Vaccine Booster,
Recruiting
- Kidney Transplant Recipients
- Liver Transplant Recipients
- Pfizer-BioNTech Bivalent COVID-19 Vaccine
- +3 more
-
San Diego, California
- +14 more
Oct 31, 2022
Corona Virus Disease 2019(COVID-19) Trial in Chengdu (0.3ml of mRNA vaccine)
Enrolling by invitation
- Corona Virus Disease 2019(COVID-19)
- 0.3ml of mRNA vaccine
-
Chengdu, ChinaWest China Second University Hospital
Oct 3, 2022
SARS-CoV-2 Trial in Salvador (Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine, Cohort 2 RNA VACCINE MCTI CIMATEC
Recruiting
- SARS-CoV-2
- Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine
- +3 more
-
Salvador, Bahia, BrazilHospital da Bahia
Mar 23, 2022
Influenza, Human, COVID-19 Trial in United States (bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV)
Recruiting
- Influenza, Human
- COVID-19
- bivalent BNT162b2 (original/Omi BA.4/BA.5)
- +2 more
-
Athens, Alabama
- +18 more
Dec 22, 2022
COVID-19 Trial in Russian Federation (Double-Stranded RNA sodium salt, Placebo)
Completed
- COVID-19
- Double-Stranded RNA sodium salt
- Placebo
-
Ivanovo, Russian Federation
- +9 more
Feb 14, 2023